Enveric Biosciences, Inc.

ENVB Nasdaq CIK: 0000890821

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Mailing Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Phone (617) 444-8400
Fiscal Year End 1231
EIN 954484725

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 27, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
S-1 IPO registration statement February 10, 2026 View on SEC
8-K Current report of material events February 6, 2026 View on SEC
424B5 Prospectus supplement February 6, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 4, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 2, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
424B5 Prospectus supplement January 28, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC

Annual Reports

10-K March 27, 2026
  • Proprietary Psybrary™ platform contains over 1,000 unique psychedelic-inspired molecules.
  • Developing lead drug candidate EB-003 to provide mental health benefits without hallucinogenic effects.
View Analysis

Material Events

8-K Strategy Change December 11, 2025
High Impact
  • Stockholders approved three key proposals: issuing shares for warrants, authorizing another potential reverse stock split (1-for-5 to 1-for-15), and increasing authorized shares from 100 million to 5 billion.
  • These approvals are strategic moves aimed at maintaining Nasdaq listing, providing significant financial flexibility for future capital raises, and fulfilling existing commitments.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.